NO981864L - Oppl°sningsmetoder - Google Patents

Oppl°sningsmetoder

Info

Publication number
NO981864L
NO981864L NO981864A NO981864A NO981864L NO 981864 L NO981864 L NO 981864L NO 981864 A NO981864 A NO 981864A NO 981864 A NO981864 A NO 981864A NO 981864 L NO981864 L NO 981864L
Authority
NO
Norway
Prior art keywords
sningsmetoder
upl
proteins
biologically active
active compounds
Prior art date
Application number
NO981864A
Other languages
English (en)
Other versions
NO981864D0 (no
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO981864D0 publication Critical patent/NO981864D0/no
Publication of NO981864L publication Critical patent/NO981864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

For bedre metoder for oppløsning av biologisk aktive forbindelser, for eksempel proteiner i et hydrofobt oppløsningsmiddel.
NO981864A 1995-10-25 1998-04-24 Oppl°sningsmetoder NO981864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods
PCT/GB1996/002609 WO1997015289A1 (en) 1995-10-25 1996-10-25 Solubilisation methods

Publications (2)

Publication Number Publication Date
NO981864D0 NO981864D0 (no) 1998-04-24
NO981864L true NO981864L (no) 1998-06-24

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981864A NO981864L (no) 1995-10-25 1998-04-24 Oppl°sningsmetoder

Country Status (12)

Country Link
EP (1) EP0857061A1 (no)
JP (1) JP2000502990A (no)
KR (1) KR19990067028A (no)
CN (1) CN1202818A (no)
AU (1) AU704292B2 (no)
BR (1) BR9611343A (no)
CA (1) CA2235487A1 (no)
GB (1) GB9521805D0 (no)
NO (1) NO981864L (no)
NZ (1) NZ320442A (no)
WO (1) WO1997015289A1 (no)
ZA (1) ZA969016B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (de) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
ZA969016B (en) 1998-04-28
BR9611343A (pt) 1999-12-28
KR19990067028A (ko) 1999-08-16
CA2235487A1 (en) 1997-05-01
EP0857061A1 (en) 1998-08-12
WO1997015289A1 (en) 1997-05-01
NO981864D0 (no) 1998-04-24
NZ320442A (en) 1999-10-28
GB9521805D0 (en) 1996-01-03
AU7317896A (en) 1997-05-15
CN1202818A (zh) 1998-12-23
AU704292B2 (en) 1999-04-15
JP2000502990A (ja) 2000-03-14

Similar Documents

Publication Publication Date Title
NO981864L (no) Oppl°sningsmetoder
DK0730406T3 (da) Mikrokapsler indeholdende suspensioner af biologisk aktive forbindelser
BR0207776A (pt) Derivado de esterol, lipossomos compreendendo o mesmo, método de carga dos referidos lipossomos e uso dos mesmos
ATE203025T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
ES2088160T3 (es) Formulacion y proceso quimicos.
EA199800288A1 (ru) Производные 5-o-дезозаминил-6-o-метилэритронолида а, способ их получения и их применение для получения биологически активных продуктов
DK366889D0 (da) Peptidderivat
TR199701567T1 (xx) Rapamisin t�revleri.
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
ES2148259T3 (es) Pro-profarmacos, su produccion y uso.
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
NO982567D0 (no) Forbedret hydrogenolyse av 2,4,6,8,10,12-heksaazatetracyklo (5.5.0.05.903.11) dodekan
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
FI961437A (fi) Vaikuttavan aineen luovuttava systeemi
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DE69608414D1 (de) Als insektizid aktive zusammensetzung
SE9501285D0 (sv) a process for the production of biologically active proteins
AU4515996A (en) Methods for increasing the bioavailability of biological active agents
DE59609043D1 (de) Feste Lösungen von 1,4-Diketopyrrolopyrrolen
NO902626L (no) Fremgangsmaate for stabilisering av biologisk aktive forbindelser immobilisert paa faste faser.
DE69616944D1 (de) Verwendung von des-aspartat-angiotensin i als wirkstoff gegen herzhypertrophie
NO884721L (no) Fremgangsmaate ved fremstilling av biologisk aktive komponenter.
EE03440B1 (et) Bioloogilise toimega bensotiasolooni etaanamiinid ja nende valmistamise protsess
FI900097A0 (fi) Foerfarande foer bestaemning av den fibrin upploesande totalaktiviteten i plasma.